Veraxa Biotech (VRXA) CFO Buergermeister files initial insider Form 3

Rhea-AI Filing Summary

Veraxa Biotech Holding AG executive Buergermeister Torsten Georg Friedrich, the company’s Chief Financial Officer, has filed an initial Form 3 as an officer of the company. The data provided does not list any reportable transactions or holdings, indicating this filing is primarily an initial ownership disclosure.

Key Terms

Chief Financial Officer, Form 3, ten percent owner

3 terms

Chief Financial Officer financial

"officer_title": "Chief Financial Officer""

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

ten percent owner regulatory

""is_ten_percent_owner": 0"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 06/23/2026 - 08:54 AM Accepted by SEC EDGAR 06/09/2026 - 07:41 PM Learn about SEC filing dates

FAQ

What does the Veraxa Biotech (VRXA) Form 3 filing show?

The filing shows that Buergermeister Torsten Georg Friedrich is a reporting person as Chief Financial Officer of Veraxa Biotech Holding AG. It is an initial ownership report and, in this data, does not list any specific holdings or insider transactions.

Did the Veraxa Biotech (VRXA) CFO buy or sell shares in this Form 3?

No insider purchases or sales are shown in this Form 3 data. The transaction summary records zero buy, sell, acquire, or dispose events, indicating no reportable trading activity is included in this particular ownership report.

What role does Buergermeister Torsten Georg Friedrich hold at Veraxa Biotech (VRXA)?

Buergermeister Torsten Georg Friedrich is identified as the Chief Financial Officer of Veraxa Biotech Holding AG. In this Form 3, he is reported as an officer, with no indication that he is a director or ten percent beneficial owner of the company.

Does the Veraxa Biotech (VRXA) Form 3 include derivative securities?

The derivative section in this Form 3 data is empty, and derivativeSummary shows no entries. This means there are no reported options, warrants, or other derivative securities associated with the reporting person in this particular filing excerpt.

Are there any tax, gift, or restructuring transactions in this VRXA Form 3?

No such transactions appear in the data. The transaction summary shows zero tax withholding, zero gifts, and zero restructuring-related transactions, suggesting the filing is limited to establishing reporting status without recording related events.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Buergermeister Torsten Georg Friedrich

(Last) (First) (Middle)

TALACKER 35

(Street)

ZURICH 8001

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/09/2026

3. Issuer Name and Ticker or Trading Symbol
Veraxa Biotech Holding AG [ VRXA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Torsten Buergermeister	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)